ClinicalTrials.gg
RecruitingNCT05386173FASSprospUpdated Mar 21, 2025

Effect of Fetal Aortic Valvuloplasty on Outcomes

An observational study in Congenital Heart Disease, Aortic Valve Stenosis and Fetal Cardiac Disorder, sponsored by Queen Silvia Children's Hospital, Gothenburg, Sweden. Recruiting at 13 sites in 8 countries. Open to participants aged 23 Weeks to 31 Weeks. Per ClinicalTrials.gov, last updated 2025-03-21.

Primary conditionHypoplastic Left Heart SyndromeRegistry: Heart Defects, CongenitalReclassifiedWhy we changed it
Registry
Heart Defects, Congenital — the first condition term the registry derived for this study.
ClinicalTrials.gg
Hypoplastic Left Heart Syndrome
Why
  1. The study's listed conditions name Hypoplastic Left Heart Syndrome, a narrower term within Heart Defects, Congenital.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by Queen Silvia Children's Hospital, Gothenburg, Sweden · Observational

How we know

From the registry’s dates

  • Started Jan 2021; still recruiting 5 years 10 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
200
Ages
23 Weeks to 31 Weeks
Sex
All
01

Study summary

In one of the most severe congenital heart defects, hypoplastic left heart syndrome (HLHS), the left ventricle is underdeveloped and the prognosis is worse than in most other heart defects. The underdevelopment can occur gradually during fetal growth caused by a narrowing of the aortic valve. At some international centers, such fetuses are treated with a balloon dilation of the narrowed valve, but there is no scientifically sound evidence that this treatment is effective.

The aim of this study is: 1/ to evaluate whether balloon dilation during the fetal period of a narrowed aortic valve can reduce the risk of the left ventricle becoming underdeveloped and the baby being born with a so-called univentricular heart (HLHS); 2/ to investigate whether such treatment improves the prognosis for this group of children with a very complex and severe heart defect and 3/ to also describe side effects and risks in fetuses and mothers of the fetal procedure.

Read the detailed description

Routinely collected pre- and postnatal clinical data will be entered into a digital database and echocardiographic examinations will be uploaded to a server. A core lab will measure and analyze all echocardiographic examinations according to protocol. The growth of the left heart structures and the postnatal outcome will be compared between the intervention and non-intervention groups.

The decision whether a fetal balloon dilatation shall be attempted is not part of the study protocol. The number of examinations of mother/fetus/infant in this study is not different from the number of examinations that will be recommended for someone choosing not to be part of this study. Participation in the study does not affect the care and treatment mothers and fetuses are receiving during pregnancy, nor how the infant is examined and treated after birth.

02

Conditions studied

  • Congenital Heart Disease
  • Aortic Valve Stenosis
  • Fetal Cardiac Disorder
  • Hypoplastic Left Heart Syndrome

Browse trials for

03

In context

Hypoplastic Left Heart Syndrome Reclassified

67 studies on the registry are indexed under Hypoplastic Left Heart Syndrome; 12 are open to participants now.

This study's planned enrollment of 200 is above the median of 100 across 23 observational studies indexed under Hypoplastic Left Heart Syndrome.

Browse Hypoplastic Left Heart Syndrome studies →

Lead sponsor

This is the only study on the registry with Queen Silvia Children's Hospital, Gothenburg, Sweden as lead sponsor.

Compared within Hypoplastic Left Heart Syndrome, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Heart Defects, Congenital. The counts are of registry records indexed under each term, refreshed daily. How we classify →

04

Who can participate

Ages eligible
23 Weeks to 31 Weeks
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

The study population consists of fetuses and children with aortic valve stenosis and/or hypoplastic left heart syndrome

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

A. All of the following echocardiographic criteria need to be satisfied between 23+0 and 31+6 weeks (z-scores according to Schneider et al):

  1. Aortic valve stenosis with antegrade flow through the valve
  2. Predominantly left-to-right shunt at the atrial level
  3. Predominantly retrograde flow in the aortic arch between the first two brachiocephalic vessels
  4. Qualitatively depressed left ventricular function
  5. Left ventricular end-diastolic diameter Z-score > ±0
  6. Left ventricular inlet length in diastole :

    1. Gestational age ≤ 24+6: Z-score > ±0
    2. Gestational age 25+0 to 27+6: Z-score > -0.75
    3. Gestational age ≥ 28+0: Z-score > -1.50
  7. Mitral valve diameter in diastole Z-score > -2.0

B. All of the following postnatal treatment options need to be available: 1. Surgical or catheter based aortic valvotomy 2. Ross-Konno surgery 3. Norwood or hybrid stage-one surgery

Exclusion criteria

Exclusion Criteria:

  1. Any associated cardiac defect except persistent left superior vena cava and coarctation of the aorta
  2. Any significant (i.e. that might influence outcome) extracardiac anomaly and/or known chromosomal aberration. Also, if such a condition is present at inclusion but diagnosed only after birth the case will be retrospectively excluded.
05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
200 participants (estimated)
Target follow-up
3 Years
Patient registry
Yes

Groups and cohorts

  • Fetal intervention group

    Fetuses with aortic valve stenosis satisfying all of the inclusion/exclusion criteria

    Procedure: Fetal aortic balloon dilatation

  • Fetal non-intervention group

    Fetuses with aortic valve stenosis satisfying all of the inclusion/exclusion criteria which are identical with the criteria in the Fetal intervention group

Interventions

  • ProcedureFetal aortic balloon dilatation

    Fetal valvuloplasty will be performed as described in Arzt W, Wertaschnigg D, Veit I, Klement F, Gitter R, Tulzer G. Intrauterine aortic valvuloplasty in fetuses with critical aortic stenosis: experience and results of 24 procedures. Ultrasound Obstet Gynecol. 2011;37:689-695. with minor variations between centers involved. Technical success is defined as improved forward flow and/or new aortic regurgitation.

06

What researchers measure

Primary outcomes

  1. Transplantation-free survival

    Transplantation-free survival from fetal diagnosis to 2 years postnatal age with a biventricular circulation without pulmonary hypertension at that time. Absence of pulmonary hypertension is defined as a TR max velocity ≤ 2.8 m/s with no other echocardiographic signs of pulmonary hypertension and/or catheter data showing a mean pulmonary arterial pressure \<25 mmHg.

    Time frame: Follow-up from study inclusion during fetal life until 2 years postnatal age

Secondary outcomes

  1. Intervention-related fetal death

    Intervention-related fetal death (defined as fetal death within 24 hours of procedure)

    Time frame: From the time of fetal intervention until 24 hours after the intervention

  2. Fetal death not directly related to the intervention

    Fetal death not directly related to the intervention, except termination of pregnancy

    Time frame: From 24 hours after fetal intervention until fetal death, up to 20 weeks after study inclusion.

  3. Maternal complications to fetal intervention procedure

    Maternal complications to procedure requiring intensive care or resulting in maternal death

    Time frame: From time of fetal intervention until 24 hours after the intervention

  4. Preterm delivery

    Preterm delivery before 37 weeks gestational age

    Time frame: From time of fetal intervention until 37 weeks gestational age, maximum 14 weeks

  5. Fetal left heart growth

    Fetal left heart growth as measured with dimensions expressed a z-scores of the mitral valve diameter, left ventricular inlet length and aortic valve diameter

    Time frame: From the date of study inclusion until just before the first postnatal catheter or surgical intervention, or death, whichever comes first, total time frame 7 months

07

Study locations

13 of 13 sites recruiting
  • Fetal Cardiovascular Program, University of California San Francisco
    San Francisco, California 94158, United States
    Recruiting
  • Congenital Heart Collaborative, Nationwide Children's Hospital
    Columbus, Ohio 43205, United States
    Recruiting
  • Kinderherzzentrum Linz
    Linz, Austria
    Recruiting
  • The Hospital for Sick Children Toronto
    Toronto, Canada
    Recruiting
    • Edgar Jaeggi, Prof · Contact
    • edgar.jaeggi@sickkids.ca · Contact
  • Department of Paediatric Cardiology, Helsinki University Children's Hospital
    Helsinki, Finland
    Recruiting
  • Pediatric Cardiology - University Hospital Bonn
    Bonn, Germany
    Recruiting
  • Department of Pediatric and Congenital Cardiology, University of Heidelberg
    Heidelberg, Germany
    Recruiting
  • University hospital Technical university, mother- and-child center
    Munich, Germany
    Recruiting
  • Department of Perinatal Cardiology and Congenital Anomalies, Centre of Postgraduate Medical Education.
    Warsaw, Poland
    Recruiting
  • Fetal Medicine Unit, Dept. Obstetrics & Gynecology University Hospital 12 de Octubre
    Madrid, Spain
    Recruiting
  • Department of Pediatric Cardiology, Skane University Hospital
    Lund, Sweden
    Recruiting
  • Department of pediatric cardiology, Karolinska Institute
    Stockholm, Sweden
    Recruiting
  • Department of Pediatrics, Umeå University Hospital
    Umeå, Sweden
    Recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Jan 2021 (actual). Primary completion is estimated for Dec 2029, 107 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
May 13, 2022
First posted
May 23, 2022
StartActual
Jan 1, 2021
Primary completionEst.
Dec 31, 2029
CompletionEst.
Dec 31, 2029
Last update
Mar 21, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 21, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05386173
Lead sponsor
Queen Silvia Children's Hospital, Gothenburg, Sweden
Collaborators
Swedish Heart Lung Foundation, Sahlgrenska University Hospital
Responsible party
Mats Mellander (Associate professor, Consultant pediatric and fetal cardiology, Queen Silvia Children's Hospital, Gothenburg, Sweden) — Principal investigator
First posted
May 23, 2022
Start date
Jan 1, 2021
Primary completion
Dec 31, 2029 (estimated)
Completion
Dec 31, 2029 (estimated)
Last update
Mar 21, 2025

Study contacts

Mats Mellander, Dr, Prof
Contact
mats.mellander@vgregion.se
0046705530606
Annika Öhman, Dr, PhD
Contact
annika.ohman@vgregion.se
0046313434568

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion